---
figid: PMC3928697__IJMR-138-648-g007
figlink: /pmc/articles/PMC3928697/figure/F5/
number: Fig. 5
caption: Schematic diagram of the proposed pathway of CD33 siglec-mediated suppression
  of cellular function in Leishmania infection. On macrophage, after ligand (present
  on various pathogen surface) binding with CD33 related siglecs, immunoreceptor tyrosine-based
  inhibition motif (ITIM) present on the cytosolic portion of siglecs get activated
  by phosphorylation with SH2 family kinases (Lyn, Syk). Then Src homology 2 domain-containing
  phosphatases 1 and 2 (SHP1 and SHP2) bind with the ITIM and get activated. These
  activated SHPs further dephosphorylate various signaling molecules and suppress
  cellular activation. The target of SHPs might be p38 mitogen-activated protein kinases
  (p38 MAPK) or Akt or nuclear factor kappa-light-chain-enhancer of activated B cells
  (NF-kβ) and ultimately downregulate the effector functions of the cell. In macrophages
  this siglec-mediated pathway might regulate the polarization of macrophage function
  towards anti-inflammatory type by reducing Th1 cytokines (IFNγ) and increasing Th2
  cytokines (IL-10) along with downregulating inducible nitric oxide synthase (iNOS)
  gene expression for nitric oxide (NO) secretion.
pmcid: PMC3928697
papertitle: 'Sialic acids siglec interaction: A unique strategy to circumvent innate
  immune response by pathogens.'
reftext: Biswajit Khatua, et al. Indian J Med Res. 2013 Nov;138(5):648-662.
pmc_ranked_result_index: '82593'
pathway_score: 0.9441137
filename: IJMR-138-648-g007.jpg
figtitle: Proposed pathway of CD33 siglec-mediated suppression of cellular function
  in Leishmania infection
year: '2013'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3928697__IJMR-138-648-g007.html
  '@type': Dataset
  description: Schematic diagram of the proposed pathway of CD33 siglec-mediated suppression
    of cellular function in Leishmania infection. On macrophage, after ligand (present
    on various pathogen surface) binding with CD33 related siglecs, immunoreceptor
    tyrosine-based inhibition motif (ITIM) present on the cytosolic portion of siglecs
    get activated by phosphorylation with SH2 family kinases (Lyn, Syk). Then Src
    homology 2 domain-containing phosphatases 1 and 2 (SHP1 and SHP2) bind with the
    ITIM and get activated. These activated SHPs further dephosphorylate various signaling
    molecules and suppress cellular activation. The target of SHPs might be p38 mitogen-activated
    protein kinases (p38 MAPK) or Akt or nuclear factor kappa-light-chain-enhancer
    of activated B cells (NF-kβ) and ultimately downregulate the effector functions
    of the cell. In macrophages this siglec-mediated pathway might regulate the polarization
    of macrophage function towards anti-inflammatory type by reducing Th1 cytokines
    (IFNγ) and increasing Th2 cytokines (IL-10) along with downregulating inducible
    nitric oxide synthase (iNOS) gene expression for nitric oxide (NO) secretion.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SIGLEC1
  - MAPK1
  - IFNG
  - NR0B2
  - MAPK12
  - SIGLEC5
  - SOCS3
  - MAPK8
  - PTPN6
  - MAPK10
  - CD33
  - MAPK11
  - MAPK14
  - MAPK13
  - MAPK3
  - AKT2
  - NFKB1
  - IL10
  - AKT1
  - MAPK9
  - AKT3
genes:
- word: Siglec-1
  symbol: SIGLEC-1
  source: hgnc_alias_symbol
  hgnc_symbol: SIGLEC1
  entrez: '6614'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK1
  entrez: '5594'
- word: IFNY
  symbol: IFNG
  source: hgnc_symbol
  hgnc_symbol: IFNG
  entrez: '3458'
- word: SHP
  symbol: SHP
  source: hgnc_alias_symbol
  hgnc_symbol: NR0B2
  entrez: '8431'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
- word: (Siglec-5)
  symbol: SIGLEC5
  source: hgnc_symbol
  hgnc_symbol: SIGLEC5
  entrez: '8778'
- word: SOCS3
  symbol: SOCS3
  source: hgnc_symbol
  hgnc_symbol: SOCS3
  entrez: '9021'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK8
  entrez: '5599'
- word: SHP1/2P
  symbol: SHP-1
  source: hgnc_alias_symbol
  hgnc_symbol: PTPN6
  entrez: '5777'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK10
  entrez: '5602'
- word: CD33
  symbol: CD33
  source: hgnc_symbol
  hgnc_symbol: CD33
  entrez: '945'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK3
  entrez: '5595'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: NF-KB
  symbol: NF-kappaB
  source: hgnc_alias_symbol
  hgnc_symbol: NFKB1
  entrez: '4790'
- word: '*IL-10'
  symbol: IL10
  source: hgnc_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK14
  entrez: '1432'
- word: p38
  symbol: p38
  source: bioentities_symbol
  hgnc_symbol: MAPK13
  entrez: '5603'
- word: IL-10
  symbol: IL-10
  source: hgnc_alias_symbol
  hgnc_symbol: IL10
  entrez: '3586'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK9
  entrez: '5601'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK11
  entrez: '5600'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MAPK
  symbol: MAPK
  source: bioentities_symbol
  hgnc_symbol: MAPK12
  entrez: '6300'
chemicals: []
diseases: []
---
